SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

13 Aug 2024 Evaluate
Revenue showed a marginal decline at Rs. 1.66 millions. For the quarter ended June 2024, as compared to corresponding quarter of last year.The Net Loss for the quarter ended June 2024 is Rs. -16.24 millions as compared to Net Loss of Rs. -13.38 millions of corresponding quarter ended June 2023 Operating profit Margin for the quarter ended June 2024 further decreased to -17.14% as compared to -12.35% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 1.66 0.00 0.00 1.66 0.00 0.00 0.28 0.00 0.00
Other Income 0.03 3.72 -99.19 0.03 3.72 -99.19 7.95 0.00 0.00
PBIDT -17.14 -12.35 38.79 -17.14 -12.35 38.79 -55.76 -98.91 -43.63
Interest 0.13 0.01 1200.00 0.13 0.01 1200.00 3.33 0.00 0.00
PBDT -17.27 -12.36 39.72 -17.27 -12.36 39.72 -59.09 -98.91 -40.26
Depreciation 0.48 0.08 500.00 0.48 0.08 500.00 1.77 0.17 941.18
PBT -17.75 -12.44 42.68 -17.75 -12.44 42.68 -60.86 -99.08 -38.57
TAX -1.51 0.94 -260.64 -1.51 0.94 -260.64 -11.37 -23.52 -51.66
Deferred Tax -1.51 0.94 -260.64 -1.51 0.94 -260.64 -11.37 -23.52 -51.66
PAT -16.24 -13.38 21.38 -16.24 -13.38 21.38 -49.49 -75.56 -34.50
Equity 352.68 214.44 64.47 352.68 214.44 64.47 352.68 214.44 64.47
PBIDTM(%) -1032.53 0.00 0.00 -1032.53 0.00 0.00 -19914.29 0.00 0.00

Pharmaids Pharma Share Price

30.92 -0.49 (-1.56%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×